Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing Press Release Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…CertaraApril 14, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…CertaraMarch 20, 2025
How biosimulation and virtual trials can bust through clinical trial roadblocks Press Coverage How biosimulation and virtual trials can bust through clinical trial roadblocks Discover how using biosimulation for rare disease drug development can help overcome statistical and recruitment…CertaraMarch 14, 2025
MIDD in Japan – Implementations, challenges and opportunities Publication MIDD in Japan – Implementations, challenges and opportunities In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…CertaraMarch 12, 2025
Model-Informed Drug Development in the Age of AI On-Demand Webinar Model-Informed Drug Development in the Age of AI Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…CertaraMarch 10, 2025
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach Publication Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…CertaraMarch 4, 2025
Machine Learning for PK/PD Modeling in Drug Development Blog Machine Learning for PK/PD Modeling in Drug Development Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…CertaraMarch 4, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement Publication The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…CertaraFebruary 25, 2025
Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA) Fact Sheet Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA) CertaraFebruary 19, 2025
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Today's drug candidates are more complex than ever. But with development decisions on the line,…CertaraFebruary 12, 2025